argenx data put myasthenia gravis therapy a step closer to challenging Soliris, raising year’s second-biggest follow-on

Armed with pivotal data showing efficacy for its myasthenia gravis candidate, argenx plans to submit a BLA by year-end for efgartigimod. If approved, it would provide patients with an alternative mechanism to that of Alexion’s Soliris eculizumab.

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) gained €43.40 (30%) to €190 in Brussels and $54.16 (34%) to $212.12 in New York on Tuesday after reporting the FCRN-binding antibody fragment met the primary endpoint in the Phase III ADAPT trial to treat generalized myasthenia gravis...